Oncology-focused digital therapeutics firm Mika Well being introduced a partnership with pharma corporations AstraZeneca and Daiichi Sankyo for an initiative dubbed “UNITE” to supply digital therapeutics to girls present process breast most cancers remedies.
Mika Well being’s app offers most cancers sufferers entry to psychological assist to scale back disease-related nervousness, despair and stress. Sufferers can monitor uncomfortable side effects from medicines, obtain medicine reminders, get hold of training and diet recommendation, and coordinate appointments.
The digital therapeutic, already licensed as a medical gadget and launched within the EU, might be customized to a person’s particular sort of most cancers.
By the partnership, Mika Well being’s choices can be used alongside pharmaceutical remedy.
German-speaking sufferers in Switzerland can first entry the providing, after which the businesses will develop to incorporate Switzerland’s French- and Italian-speaking areas.
“Digital therapies have gotten more and more vital in fashionable most cancers therapy,” Adam Nosal, head of oncology at AstraZeneca Switzerland, stated in an announcement. “This partnership with Mika permits us to develop entry to holistic most cancers care and acquire insights that may form our broader efforts to enhance therapeutic choices for most cancers sufferers.”
THE LARGER TREND
In June, Mika Well being and the worldwide nonprofit Most cancers Assist Group introduced they are going to present an AI-enabled oncology-focused digital therapeutic for U.S.-based most cancers sufferers and their caregivers to entry psychological well being and different assist providers freed from cost.
Earlier this 12 months, the corporate introduced a partnership with AI oncology agency Huge Bio to supply free entry to Miko’s choices via Huge Bio’s platform.
Mika sufferers would even be given the power to take part in Huge’s AI-enabled biomarker testing and medical trial matching choices.
The HIMSS AI in Healthcare Discussion board is scheduled to happen September 5-6 in Boston. Study extra and register.
